Test Price
4,600 AED✅ Home Collection Available
Oncomine Chronic Myelomonocytic Leukemia (CMML) Panel Test – Dubai, UAE
Executive Summary & Core Metrics
- Diagnostic Sensitivity: >99.9% via ISO‑certified NGS processing.
- Collection Logistics: Hospital Extraction Only – Sample collection is conducted strictly within an accredited hospital facility; mobile home phlebotomy is disabled for safety.
- Post‑Test Guidance: Complimentary telephonic consultation with a clinical geneticist to interpret results in your medical context.
- Insurance Verification: Direct billing check via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The Oncomine Chronic Myelomonocytic Leukemia (CMML) Panel uses targeted Next‑Generation Sequencing (NGS) to detect somatic mutations in key genes associated with CMML. This provides clinicians with a comprehensive molecular profile for accurate diagnosis, risk stratification, and personalised therapeutic planning. The test is performed on whole blood or bone marrow aspirate collected under strict hospital‑based protocols.
| Feature | Our Oncomine CMML Panel (NGS) | Conventional Karyotyping / FISH |
|---|---|---|
| Precision | >99% detection of clinically relevant gene mutations | Limited resolution; misses sub‑microscopic variants |
| Methodology | Targeted NGS panel with ISO‑certified bioinformatics pipeline | Cell culture‑dependent, visual banding analysis |
| Turnaround Time | Results in ~2–4 weeks (batched 1st/16th of month) | Typically 3–6 weeks |
Sample Requirement: 3 mL whole blood (2 mL minimum – Lavender top EDTA tube) OR 2 mL bone marrow aspirate. Ship refrigerated; DO NOT FREEZE. A completed NGS Test Requisition Form (Form 40) is mandatory.
Pre‑test Instructions: No dietary or drug restrictions. Disclose all anticoagulant and antiplatelet medications to the collecting clinician. Consent will be obtained in accordance with Federal Decree‑Law No. 4 of 2016.
Physician Insight & Safety Protocols
“This NGS panel provides a detailed molecular snapshot of your disease, yet every result must be integrated with your full clinical picture—blood counts, physical examination, and bone marrow morphology. I recommend discussing all findings with your treating hemato‑oncologist before making treatment decisions.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics (DHA Registration ID: 9294403)
Safety Exclusion Criteria & Emergency Red Flags
Absolute Contraindications
- Active, uncontrolled hemorrhage or severe thrombocytopenia with spontaneous bleeding.
- Inability to provide informed consent or unconfirmed clinical suspicion of CMML.
- Acute infection requiring immediate antimicrobial therapy – postpone the draw.
🚨 Urgent medical attention required if you develop: sudden fever (>38.5°C), severe bone pain, uncontrolled bleeding, or altered consciousness.
Medication Warning
⚠️ Do not discontinue prescribed anticoagulants, antiplatelets, or any other medication without consulting your doctor. The NGS test does not require therapy interruption.
Patient FAQ & Clinical Guidance
1. What is the Oncomine CMML Panel and who needs it?
This advanced genetic test screens multiple genes simultaneously, identifying mutations that confirm CMML diagnosis and risk stratification. It is indicated when routine blood work suggests myelodysplasia or myeloproliferative features, helping oncologists and hematologists tailor therapy.
2. How do I prepare for the test?
Provide a blood or bone marrow sample as instructed under hospital conditions. No fasting is needed. Ensure the NGS Test Requisition Form (Form 40) is completed accurately and your contact details are up‑to‑date.
3. When will I receive my results?
Reports are released bi‑monthly: samples drawn by the 1st of the month are reported by the 15th; samples drawn by the 16th are reported on the 30th. This ensures consistent turnaround regardless of your clinical schedule.
UAE Regulatory & Data Privacy Adherence
Your Data, Our Commitment
- Personal Data Protection: All genetic and personal information is handled in strict compliance with Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL).
- Health Information Security: Electronic health records and diagnostic data are safeguarded under Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields.
- Informed Consent & Medical Liability: Patient consent and clinical safety procedures adhere to Federal Decree‑Law No. 4 of 2016 on Medical Liability.
- Accreditation: All processes are certified under ISO 9001:2015 (Cert: INT/EGQ/2509DA/3139).
Clinical & Logistical Metadata
| Test Name | Oncomine Chronic Myelomonocytic Leukemia (CMML) Panel |
| Price (AED) | 4,600 |
| Turnaround Time | 2–4 weeks (batched 1st and 16th of each month) |
| Sample Type / Matrix | Whole blood (3 mL, EDTA) OR bone marrow aspirate (2 mL) – Hospital Extraction Only |
| Methodology Used | Targeted Next‑Generation Sequencing (NGS) with ISO‑certified bioinformatics pipeline |
| ICD-10-CM Code | C93.10 (Chronic myelomonocytic leukemia, not having achieved remission) |
| LOINC Code | 103136-6 |
| DHA Facility License & Lab Address | License No. 1143 – Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE – DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians